Big tech’s biggest acquisitions. French tech funding. Ant & Tencent’s growth playbooks.
What’s the score?
Hi there,
Folks have been talking about using data to assess the health/traction of private tech companies for a while now.
We at CB Insights were initially funded by a National Science Foundation SBIR grant to tackle this. So we built our Mosaic score to try to track private company health. It rates companies across 3 dimensions:
Market
Money
Momentum
It’s done pretty well. In 2015, we worked with the New York Times to identify 50 future unicorns, and as of February 2019, 24 (48% of our picks) hit the $1B mark.
But the one “M” missing from the Mosaic model is Management.
And so we’ve wondered if we can build a score to understand if individuals or a team are exceptional. There are some basic signals that we know folks use around credentials/pedigree, aka “pattern matching”:
School, e.g. Stanford, Ivy League
Former employers, e.g. Xooglers
But if you were building a score to assess team/individual exceptionalism, what would the less obvious signals be?
More on this below.
AND NOW, THE RESEARCH
Silicon Valley Pacman
With Google’s $2.1B acquisition of FitBit, FAMGA cos (Facebook, Apple, Microsoft, Google, and Amazon) have now made 27 billion-dollar acquisitions over the last 20 years.
Here are a few potential signifiers of team/individual exceptionalism (some are better than others):
Twitter followers
Patents
Published research
Network centrality (connectedness to other exceptional people)
Career/promotion trajectory
Yes, there are Black Mirror-ish aspects to doing this, for sure.
In our internal discussions about this at CBI, that’s one of the first concerns that comes up (beyond how difficult it might actually be). But it’s still an interesting challenge to think about.
Three-quarters of CVCs face the challenge of balancing strategic and financial objectives, according to a recent Growth Collective survey.
Want to learn more about CVC objectives and exchange best practices with other execs?
Growth Collective is an exclusive network with access to senior-level peers, actionable tools, and evidence-based insights to help you overcome corporate growth challenges. Apply here to learn more.
CLIENT-EXCLUSIVE RESEARCH
Trippin’ out
Psychedelics could be the next cannabis, with investors and researchers alike starting to look at how the drug category could help treat illnesses.
All the data in this newsletter comes from CB Insights.
Join NEA, Cisco, & hundreds of other clients and get
access to the industry’s best private company data.